isn't early enough
Almost 90% of liver cancer is made up of hepatocellular carcinoma (HCC).
Patients at risk for HCC include those with: pre-existing cirrhosis, chronic hepatitis B or hepatitis C, excessive alcohol use, and nonalcoholic fatty liver disease (NAFLD). Less-prevalent conditions, such as hereditary hemochromatosis, primary biliary cholangitis (PBC), and Wilson's disease, have also been associated with HCC development.
By combining the results of cell-free DNA methylation testing with data from protein tumor markers and other clinical information, the HelioLiver test delivers superior performance characteristics when compared to traditional blood tests for hepatocellular carcinoma (HCC)
| HELIOLIVER 91% Specificity | AFP | GALAD | |
|---|---|---|---|
| Early Stage Sensitivity | 76% | 57% | 65% |
| Overall Sensitivity | 85% | 62% | 75% |
| Early Stage Sensitivity | |
|---|---|
| HELIOLIVER (91% SPECIFICITY) | 76% |
| AFP | 57% |
| GALAD | 65% |
| Overall Sensitivity | |
|---|---|
| HELIOLIVER (91% SPECIFICITY) | 85% |
| AFP | 62% |
| GALAD | 75% |
Offered exclusively via our partner
Helio Genomics has partnered with the NGS pioneers at Fulgent Genetics to revolutionize cancer diagnostic technology and provide the highest standards of care with CLIA and CAP-certified laboratories.